Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-cash Items (2016 - 2021)

ImmunityBio (IBRX) has disclosed Non-cash Items for 8 consecutive years, with $16.2 million as the latest value for Q2 2021.

  • On a quarterly basis, Non-cash Items fell 46.63% to $16.2 million in Q2 2021 year-over-year; TTM through Jun 2021 was $16.2 million, a 46.63% decrease, with the full-year FY2020 number at $29.7 million, up 420.95% from a year prior.
  • Non-cash Items was $16.2 million for Q2 2021 at ImmunityBio, up from $13.9 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $40.9 million in Q1 2017 to a low of $353000.0 in Q2 2019.
  • A 5-year average of $11.8 million and a median of $7.2 million in 2018 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 95.28% in 2018, then soared 8498.87% in 2020.
  • ImmunityBio's Non-cash Items stood at $11.9 million in 2017, then plummeted by 95.28% to $563000.0 in 2018, then surged by 914.21% to $5.7 million in 2019, then skyrocketed by 420.95% to $29.7 million in 2020, then plummeted by 45.54% to $16.2 million in 2021.
  • Per Business Quant, the three most recent readings for IBRX's Non-cash Items are $16.2 million (Q2 2021), $13.9 million (Q1 2021), and $29.7 million (Q4 2020).